AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26983642 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PSORI-CM01 plus topical sequential therapy
Number of subjects: 17
Study 26983642 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus topical sequential therapy
Number of subjects: 17
Study 26983642 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PSORI-CM01
Number of subjects: 17
Study 26983642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 23759828 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECEDE-PROCEED educational program
Number of subjects: 0
Study 22490715 — intervention group
Group type: EXPERIMENTAL
Intervention: CSWT (shots/spot at 0.09 mJ/mm(2) for 9 spots, 9 times within 3 months)
Number of subjects: 50
Study 22490715 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 20469954 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and educational intervention (SI)
Number of subjects: 421
Study 20469954 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (CIN)
Number of subjects: 421
Study 17892610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine (0.5%) + ketamine (0.1 mg kg‐1)
Number of subjects: 60
Study 17892610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine (0.5%) + ketamine (0.1 mg kg‐1) + midazolam (0.02 mg kg‐1)
Number of subjects: 60
Study 17892610 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal bupivacaine (0.5%)
Number of subjects: 60
Study 15950180 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-citrullinated huCI
Number of subjects: 0
Study 15950180 — intervention group
Group type: COMPARATOR
Intervention: Normal control sera
Number of subjects: 0
Study 12364444 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenoate (200 mg as an iv bolus, followed by 200 mg infused in 250 ml saline)
Number of subjects: 6
Study 12364444 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.02 mg/kg, orally)
Number of subjects: 6
Study 12364444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 10469814 — intervention group
Group type: EXPERIMENTAL
Intervention: Amethocaine gel (1 g for 30 minutes)
Number of subjects: 39
Study 10469814 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine-prilocaine cream (1 g for 60 minutes)
Number of subjects: 39
Study 8729705 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis intervention (two sessions of 45 minutes each)
Number of subjects: 2000
Study 8729705 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hypnosis)
Number of subjects: 2000
Study 8729705 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis intervention
Number of subjects: 2000
Study 1808626 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg aspirin daily
Number of subjects: 701
Study 1808626 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg aspirin daily
Number of subjects: 701
Study 1808626 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg aspirin daily
Number of subjects: 701
Study 6351586 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium supplementation (200 micrograms trivalent chromium daily for 6 weeks)
Number of subjects: 10
Study 6351586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30541041 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid (triamcinolone 20 mg)
Number of subjects: 56
Study 30541041 — intervention group
Group type: COMPARATOR
Intervention: IA saline
Number of subjects: 56
Study 28355372 — intervention group
Group type: EXPERIMENTAL
Intervention: Patent blue (group A)
Number of subjects: 142
Study 28355372 — intervention group
Group type: COMPARATOR
Intervention: Methylene blue (group B)
Number of subjects: 142
Study 26135553 — intervention group
Group type: COMPARATOR
Intervention: Single Session Counseling (SSC)
Number of subjects: 194
Study 26135553 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MINT)-TLC
Number of subjects: 194
Study 23401275 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin combined with prednisolone (treatment group, n = 28)
Number of subjects: 58
Study 23401275 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin alone (control group, n = 30)
Number of subjects: 58
Study 22946986 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin
Number of subjects: 170
Study 22946986 — intervention group
Group type: COMPARATOR
Intervention: MMF
Number of subjects: 170
Study 19388505 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative fluid bolus (up to 1,000 mL using the 4‐2‐1 formula)
Number of subjects: 46
Study 19388505 — intervention group
Group type: COMPARATOR
Intervention: Routine replacement fluids (control group)
Number of subjects: 46
Study 17451562 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 61
Study 17451562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 15164862 — intervention group
Group type: EXPERIMENTAL
Intervention: Oppositional behavior in male child actor
Number of subjects: 0
Study 15164862 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior associated with ADHD in male child actor
Number of subjects: 0
Study 15164862 — intervention group
Group type: EXPERIMENTAL
Intervention: Oppositional behavior in female child actor
Number of subjects: 0
Study 15164862 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior associated with ADHD in female child actor
Number of subjects: 0
Study 15164862 — intervention group
Group type: COMPARATOR
Intervention: Control tape (unremarkable behavior)
Number of subjects: 0
Study 11167354 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy plus training on the use of nasal spray (Group B)
Number of subjects: 101
Study 11167354 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy plus training on the use of nasal spray and a lesson on rhinitis and asthma (Group C)
Number of subjects: 101
Study 11167354 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy alone (Group A)
Number of subjects: 101
Study 11167354 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained groups (Group B and C)
Number of subjects: 101
Study 9554567 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐1 (80 µg/kg/day)
Number of subjects: 8
Study 9554567 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐1 (80 µg/kg/day) + rhGH (50 µg/kg/day)
Number of subjects: 8
Study 9554567 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 8
Study 9554567 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 8
Study 7802322 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal prosidol tablets
Number of subjects: 113
Study 7802322 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosidol for postoperative analgesia
Number of subjects: 113
Study 7802322 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosidol as a component of total anesthesia
Number of subjects: 113
Study 3197580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg intravenous bolus injection)
Number of subjects: 7
Study 31357997 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass Testing and Treatment (MTaT) delivered by community health volunteers (CHVs) three times a year for 2 years
Number of subjects: 90000
Study 31357997 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement and capacity building efforts
Number of subjects: 90000
Study 31357997 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of more than 80 Kenya MOH CHVs and other staff
Number of subjects: 90000
Study 28077091 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial approach
Number of subjects: 400
Study 28077091 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral approach
Number of subjects: 400
Study 28077091 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 400
Study 25903751 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloth masks
Number of subjects: 1607
Study 25903751 — intervention group
Group type: COMPARATOR
Intervention: Medical masks
Number of subjects: 1607
Study 25903751 — intervention group
Group type: COMPARATOR
Intervention: Control (usual practice)
Number of subjects: 1607
Study 23562254 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular drainage for 48 hours
Number of subjects: 0
Study 23562254 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular drainage for 24 hours
Number of subjects: 0
Study 21761706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration of allergen (SLIT)
Number of subjects: 52
Study 21761706 — intervention group
Group type: COMPARATOR
Intervention: Nasal spray of budesonide (Control)
Number of subjects: 52
Study 19258920 — intervention group
Group type: EXPERIMENTAL
Intervention: Motavizumab 15 mg/kg
Number of subjects: 217
Study 19258920 — intervention group
Group type: EXPERIMENTAL
Intervention: Motavizumab
Number of subjects: 217
Study 19258920 — intervention group
Group type: COMPARATOR
Intervention: Palivizumab 15 mg/kg
Number of subjects: 217
Study 16961676 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug only (orlistat)
Number of subjects: 250
Study 16961676 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug + brief counselling
Number of subjects: 250
Study 16961676 — intervention group
Group type: COMPARATOR
Intervention: Brief counselling only
Number of subjects: 250
Study 15532817 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine administered at an early stage after bowel surgery while receiving parenteral nutrition
Number of subjects: 0
Study 15532817 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11683207 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin‐releasing hormone agonist (GnRHa) alone or in combination with growth hormone (GH) for 3 years
Number of subjects: 30
Study 9804577 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (HP; 1.8 g . kg‐1 . day‐1)
Number of subjects: 16
Study 9804577 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet (LP; 0.7 g . kg‐1 . day‐1)
Number of subjects: 16
Study 9804577 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 16
Study 7933348 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V (500 mg twice a day)
Number of subjects: 551
Study 7933348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study 3415422 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of fluphenazine decanoate (average, 25 mg every two weeks)
Number of subjects: 70
Study 3415422 — intervention group
Group type: COMPARATOR
Intervention: Minimal dose of fluphenazine decanoate (average, 3.8 mg every two weeks)
Number of subjects: 70
Study 30768663 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal hex and convergent transmucosal collar implants
Number of subjects: 61
Study 30768663 — intervention group
Group type: EXPERIMENTAL
Intervention: Supracrestally placed implants
Number of subjects: 61
Study 29941500 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine followed by metformin for 3 months and then metformin for 9 months
Number of subjects: 91
Study 29941500 — intervention group
Group type: COMPARATOR
Intervention: Metformin alone for 12 months
Number of subjects: 91
Study 29941500 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 91
Study 29941500 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine followed by metformin
Number of subjects: 91
Study 29941500 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 91
Study 27106241 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (CRT)
Number of subjects: 81
Study 24345601 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week web-based physical activity intervention
Number of subjects: 397
Study 24345601 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 397
Study 22931173 — intervention group
Group type: EXPERIMENTAL
Intervention: Model vehicle demonstrating risky behavior (running a yellow light)
Number of subjects: 0
Study 22931173 — intervention group
Group type: EXPERIMENTAL
Intervention: Model vehicle demonstrating safe behavior (stopping at the intersection)
Number of subjects: 0
Study 22931173 — intervention group
Group type: EXPERIMENTAL
Intervention: Model vehicle demonstrating safe and risky behaviors
Number of subjects: 0
Study 22931173 — intervention group
Group type: EXPERIMENTAL
Intervention: Model vehicle demonstrating safe behavior
Number of subjects: 0
Study 20700680 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (non-stimulating catheter insertion)
Number of subjects: 80
Study 20700680 — intervention group
Group type: COMPARATOR
Intervention: Stimulating catheter technique (electrical stimulation)
Number of subjects: 80
Study 17693905 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled steroid, Budesonide (0.25 mg/2 mL)
Number of subjects: 32
Study 17693905 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo (2 mL of inhaled 0.9% saline)
Number of subjects: 32
Study 15856454 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 117
Study 15856454 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 117
Study 12040440 — intervention group
Group type: EXPERIMENTAL
Intervention: BFM-oriented therapy without cranial irradiation
Number of subjects: 467
Study 12040440 — intervention group
Group type: COMPARATOR
Intervention: High doses of L-asparaginase (HD-L-ASP) during maintenance treatment
Number of subjects: 467
Study 12040440 — intervention group
Group type: COMPARATOR
Intervention: High doses of intravenous 6-mercaptopurine (HD-6MP) during protocol M
Number of subjects: 467
Study 10514950 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 10514950 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST-PC)
Number of subjects: 0
Study 10514950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7488410 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI 120 mg/m2 every 3 weeks
Number of subjects: 45
Study 7488410 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI 120 mg/m2 + LND (150 mg on day 1, 300 mg on day 2, 450 mg on days 3-5)
Number of subjects: 45
Study 7488410 — intervention group
Group type: COMPARATOR
Intervention: All patients
Number of subjects: 45
Study 2139996 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil hydrochloride aerosol therapy (10 mg/day on days 10, 12, 14, 16, 18, 20, 22)
Number of subjects: 40
Study 2139996 — intervention group
Group type: COMPARATOR
Intervention: Speleotherapy
Number of subjects: 40
Study 7377255 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of estradiol valerate
Number of subjects: 100
Study 7377255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31464912 — intervention group
Group type: EXPERIMENTAL
Intervention: SOCG (SOCG tablet)
Number of subjects: 148
Study 31464912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 28716152 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intervention consisting of 27 behaviour change techniques (BCTs)
Number of subjects: 76
Study 28716152 — intervention group
Group type: EXPERIMENTAL
Intervention: Researcher panel opinion for BCT selection
Number of subjects: 76
Study 25564797 — intervention group
Group type: EXPERIMENTAL
Intervention: PCL-based dermal filler
Number of subjects: 40
Study 25564797 — intervention group
Group type: COMPARATOR
Intervention: NASHA-based dermal filler
Number of subjects: 40
Study 24194293 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir (NFV) 1,250 mg bid concurrent with temozolomide (TMZ) 150-200 mg/m(2) and radiotherapy (6,000 cGy)
Number of subjects: 21
Study 24194293 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir (NFV) 625 mg bid concurrent with temozolomide (TMZ) and radiotherapy
Number of subjects: 21
Study 21992010 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoprene wrist/hand splint
Number of subjects: 4
Study 21992010 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of the splint
Number of subjects: 4
Study 20810596 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics plus cognitive-behavioral therapy
Number of subjects: 33
Study 20810596 — intervention group
Group type: COMPARATOR
Intervention: Second-generation antipsychotics alone
Number of subjects: 33
Study 17983301 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit self-esteem measures under threat conditions
Number of subjects: 4
Study 17983301 — intervention group
Group type: COMPARATOR
Intervention: Self-affirmation intervention
Number of subjects: 4
Study 17983301 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat manipulations
Number of subjects: 4
Study 17983301 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretest anxiety
Number of subjects: 4
Study 17983301 — intervention group
Group type: EXPERIMENTAL
Intervention: ISEC among high-threat participants
Number of subjects: 4
Study 15250203 — intervention group
Group type: EXPERIMENTAL
Intervention: Chuankezhi injection
Number of subjects: 68
Study 15250203 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo injection
Number of subjects: 68
Study 12431243 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral taurine (1000 mg d(-1))
Number of subjects: 51
Study 12431243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 9836523 — intervention group
Group type: EXPERIMENTAL
Intervention: IDDM patients with a history of hypoglycemic coma
Number of subjects: 108
Study 9836523 — intervention group
Group type: EXPERIMENTAL
Intervention: IDDM patients without a history of hypoglycemic coma
Number of subjects: 108
Study 9836523 — intervention group
Group type: EXPERIMENTAL
Intervention: IDDM patients
Number of subjects: 108
Study 9836523 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 108
Study 8137333 — intervention group
Group type: COMPARATOR
Intervention: Daily supplementation with 26 vitamins and minerals for 6 years
Number of subjects: 3318
Study 8137333 — intervention group
Group type: COMPARATOR
Intervention: Retinol and zinc supplementation
Number of subjects: 3318
Study 8137333 — intervention group
Group type: COMPARATOR
Intervention: Beta-carotene, vitamin E, and selenium supplementation
Number of subjects: 3318
Study 2680230 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate meal
Number of subjects: 7
Study 2680230 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein meal
Number of subjects: 7
Study 2680230 — intervention group
Group type: COMPARATOR
Intervention: Normal (mixed) meal
Number of subjects: 7
Study 2680230 — intervention group
Group type: COMPARATOR
Intervention: High fat meal
Number of subjects: 7
Study 2680230 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal
Number of subjects: 7
Study 477258 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium chloride (50 mmol three times daily for 3 days)
Number of subjects: 4
Study 477258 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium chloride (50 mmol in 50 ml over 22 min)
Number of subjects: 4
Study 30447946 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed RBCs greater than or equal to 22 days old
Number of subjects: 678
Study 30447946 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed RBCs 0 to 7 days old
Number of subjects: 678
Study 30447946 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed RBCs 8 to 14 days old
Number of subjects: 678
Study 30447946 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed RBCs 15 to 21 days old
Number of subjects: 678
Study 27480445 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 3110
Study 27480445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3110
Study 27480445 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 3110
Study 26501788 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 33
Study 26501788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 23941366 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental exposures and gene-environment interactions
Number of subjects: 1400
Study 21304064 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery (GB)
Number of subjects: 15
Study 21304064 — intervention group
Group type: COMPARATOR
Intervention: Lean subjects (L)
Number of subjects: 15
Study 21304064 — intervention group
Group type: COMPARATOR
Intervention: Obese subjects (O)
Number of subjects: 15
Study 19809308 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 88
Study 19809308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 19225128 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk/peanut FS
Number of subjects: 1362
Study 19225128 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy/peanut FS
Number of subjects: 1362
Study 19225128 — intervention group
Group type: COMPARATOR
Intervention: CSB
Number of subjects: 1362
Study 15262693 — intervention group
Group type: COMPARATOR
Intervention: MT‐1 (0.08 mg/kg per day subcutaneously) with UV‐B light (3 times the minimal erythema dose) for 10 days
Number of subjects: 28
Study 15262693 — intervention group
Group type: EXPERIMENTAL
Intervention: MT‐1 (0.16 mg/kg per day) with UV‐B radiation (0.25‐0.75 MED) for 10 days
Number of subjects: 28
Study 15262693 — intervention group
Group type: EXPERIMENTAL
Intervention: MT‐1 (0.16 mg/kg) for 5 days per week for 4 weeks with sunlight
Number of subjects: 28
Study 15262693 — intervention group
Group type: COMPARATOR
Intervention: Sunlight only
Number of subjects: 28
Study 12596615 — intervention group
Group type: EXPERIMENTAL
Intervention: Body acupuncture during three consecutive days immediately before induction of ROD
Number of subjects: 40
Study 12596615 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 40
Study 9832091 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral annular calcium (MAC) group
Number of subjects: 165
Study 9832091 — intervention group
Group type: COMPARATOR
Intervention: Control group (without MAC)
Number of subjects: 165
Study 7807244 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching intervention on pressure ulcer risk, assessment, and treatment
Number of subjects: 102